What causes protein aggregation and how is it prevented in biopharmaceuticals?

Protein aggregation compromises safety (immunogenicity) and efficacy. Causes: 1) Physical stress - agitation, freezing/thawing, shear stress. 2) Chemical stress - oxidation, deamidation, fragmentation. 3) Thermal stress - temperature excursions. 4) Interfaces - air-water, ice-water, container surfaces. 5) Concentration - high protein concentrations increase collision probability. Prevention strategies: Formulation - stabilizing excipients (sugars like sucrose/trehalose, surfactants like polysorbate 80, amino acids like arginine), pH optimization (away from pI), ionic strength. Process - controlled mixing, minimize freeze-thaw cycles, appropriate filters/tubing materials. Container - suitable materials, surfactant-coated, minimize headspace. Storage - appropriate temperature, protected from light. Monitoring - SEC, DLS, turbidity, subvisible particle counting. Quality control limits for aggregates (typically <1-2%). Visible particles absolutely not acceptable.